Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News Archive
Showing 1835 results
August 2019
-
Story Discovery
Using Super-Resolution Microscopy To See Neurodegeneration
Novartis data scientists are using super-resolution microscopy to see neurodegeneration the moment it starts.
-
Press Release
Novartis stands behind Zolgensma® (onasemnogene abeparvovec-xioi) for the treatment of children less than 2 years of age with spinal muscular atrophy
Basel, August 6, 2019 – Today the FDA released a statement addressing data integrity issues with the Biologics License Application (BLA) for Zolgensma® (onasemnogene abeparvovec-xioi). First and… -
Story Discovery
Keeping the heart of patients at the heart of everything we do
For over 60 years Novartis has been committed to helping people with cardiovascular disease and we remain steadfast in that commitment to this day.
July 2019
-
Press Release
Novartis Kisqali significantly prolongs life in women with HR+/HER2- advanced breast cancer now in two distinct Phase III trials
In MONALEESA-3, Kisqali plus fulvestrant achieved statistically significant improvement in overall survival in post-menopausal women in first- and second-line setting Kisqali is the only CDK4/6… -
Story People and Culture
Q&A with new NIBR CIO Dimitris Agrafiotis
The Chief Information Officer of the Novartis Institutes for BioMedical Research discusses his new role.
-
Key Release
Novartis provides update on Phase III PARAGON-HF trial in heart failure patients with preserved ejection fraction (HFpEF)
PARAGON study narrowly misses statistical significance on the primary endpoint; overall safety profile confirmed Totality of evidence suggests potential clinically important benefit; results will… -
Press Release
Novartis receives positive CHMP opinion for Lucentis® treatment in preterm infants with retinopathy of prematurity (ROP), a disease causing visual impairment and blindness
Lucentis (ranibizumab), if approved in the EU for this indication, will be the first and only pharmacological therapy for ROP in these vulnerable infants Positive opinion is based on the landmark… -
Story From Our Labs
Hardwiring the future
A Cell & Gene production unit staffed by a highly trained team at Novartis will soon begin operating in Stein, Switzerland.
-
Press Release
AveXis Statement on Access to Zolgensma® (onasemnogene abeparvovec-xioi)
The FDA's May 2019 approval of Zolgensma ®, a gene therapy for spinal muscular atrophy (SMA) in pediatric patients less than 2 years of age, marked an important milestone within the SMA community.… -
Story People and Culture
Flexibility at Novartis: Linda Karpiak
Karpiak explains how her flexible schedule enables her to succeed at work while staying active in her community.
-
Press Release
Sandoz announces first patient enrolled in clinical study for proposed biosimilar denosumab in osteoporosis
Integrated Phase I/lll study for proposed biosimilar denosumab to confirm matching efficacy, safety and immunogenicity with reference medicine[1] Osteoporosis accounts for 8.9m bone fractures… -
Press Release
Novartis key multiple sclerosis product Gilenya® approved in China
Chinese National Medical Products Administration (NMPA) approved Gilenya® for relapsing forms of multiple sclerosis (RMS) for adults and children 10 years and older. Multiple sclerosis (MS) is…